Loading…
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma
Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy is standard of care in multiple myeloma (MM). While short‐term quality of life (QOL) deterioration after AHCT is known, the long‐term trajectories and symptom burden after transplantation are largely...
Saved in:
| Published in: | American journal of hematology 2023-01, Vol.98 (1), p.140-147 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4086-fe1c59942ad6f4740eac366bda173a025cac041cea11faf9bf54674665be85b33 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4086-fe1c59942ad6f4740eac366bda173a025cac041cea11faf9bf54674665be85b33 |
| container_end_page | 147 |
| container_issue | 1 |
| container_start_page | 140 |
| container_title | American journal of hematology |
| container_volume | 98 |
| creator | D'Souza, Anita Brazauskas, Ruta Stadtmauer, Edward A. Pasquini, Marcelo C. Hari, Parameswaran Bashey, Asad Callander, Natalie Devine, Steven Efebera, Yvonne Ganguly, Siddhartha Gasparetto, Cristina Geller, Nancy Horowitz, Mary M. Koreth, John Landau, Heather Brunstein, Claudio McCarthy, Philip Qazilbash, Muzaffar H. Giralt, Sergio Krishnan, Amrita Flynn, Kathryn E. |
| description | Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy is standard of care in multiple myeloma (MM). While short‐term quality of life (QOL) deterioration after AHCT is known, the long‐term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. FACT‐BMT scores up to 4 years post‐AHCT were analyzed. Symptom burden was studied using responses to 17 individual symptoms dichotomized as ‘none/mild’ for scores 0–2 and ‘moderate/severe’ for scores of 3 or 4. Patients with no moderate/severe symptom ratings were considered to have low symptom burden at 1‐year. Mean age at enrollment was 55.5 years with 17% African Americans. Median follow‐up was 6 years (range, 0.4–8.5 years). FACT‐BMT scores improved between enrollment and 1‐year and remained stable thereafter. Low symptom burden was reported by 27% of patients at baseline, 38% at 1‐year, and 32% at 4 years post‐AHCT. Predictors of low symptom burden at 1‐year included low symptom burden at baseline: OR 2.7 (1.8–4.1), p |
| doi_str_mv | 10.1002/ajh.26596 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9659666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2664790519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4086-fe1c59942ad6f4740eac366bda173a025cac041cea11faf9bf54674665be85b33</originalsourceid><addsrcrecordid>eNp1kUFv1DAQhS0EokvhwB9AlrjQw7Z2EtvJBamqKAVV4lLO1sQ77nrl2KnttMqZP06WLRUgcZqR5tPTe_MIecvZKWesOoPd9rSSopPPyIqzTq5bKarnZMVqyZeddUfkVc47xjhvWvaSHNVCSKVUuyI_bhLs0JSYHGYaLb2bwLsy71fvLNKEJt5jmimEDc3zMJY40H5KGwwUbMFEYSrRx9s4ZbrFAUoco8PiDDXoPS0JQh49hALFxUBdoMPkixs90mFGHwd4TV5Y8BnfPM5j8v3y083F1fr62-cvF-fXa9OwVq4tciO6rqlgI22jGoZgain7DXBVA6uEAcMabhA4t2C73opGqkZK0WMr-ro-Jh8PuuPUD7gxGBZzXo_JDZBmHcHpvy_BbfVtvNfd_rdSLgIfHgVSvJswFz24vE8JAZf4upKyUR0TvFvQ9_-guzilsMTTlRJCtW1bqYU6OVAmxZwT2icznOl9tXqpVv-qdmHf_en-ifzd5QKcHYAH53H-v5I-_3p1kPwJWp2yWA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2755788827</pqid></control><display><type>article</type><title>Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma</title><source>Wiley</source><creator>D'Souza, Anita ; Brazauskas, Ruta ; Stadtmauer, Edward A. ; Pasquini, Marcelo C. ; Hari, Parameswaran ; Bashey, Asad ; Callander, Natalie ; Devine, Steven ; Efebera, Yvonne ; Ganguly, Siddhartha ; Gasparetto, Cristina ; Geller, Nancy ; Horowitz, Mary M. ; Koreth, John ; Landau, Heather ; Brunstein, Claudio ; McCarthy, Philip ; Qazilbash, Muzaffar H. ; Giralt, Sergio ; Krishnan, Amrita ; Flynn, Kathryn E.</creator><creatorcontrib>D'Souza, Anita ; Brazauskas, Ruta ; Stadtmauer, Edward A. ; Pasquini, Marcelo C. ; Hari, Parameswaran ; Bashey, Asad ; Callander, Natalie ; Devine, Steven ; Efebera, Yvonne ; Ganguly, Siddhartha ; Gasparetto, Cristina ; Geller, Nancy ; Horowitz, Mary M. ; Koreth, John ; Landau, Heather ; Brunstein, Claudio ; McCarthy, Philip ; Qazilbash, Muzaffar H. ; Giralt, Sergio ; Krishnan, Amrita ; Flynn, Kathryn E.</creatorcontrib><description>Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy is standard of care in multiple myeloma (MM). While short‐term quality of life (QOL) deterioration after AHCT is known, the long‐term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. FACT‐BMT scores up to 4 years post‐AHCT were analyzed. Symptom burden was studied using responses to 17 individual symptoms dichotomized as ‘none/mild’ for scores 0–2 and ‘moderate/severe’ for scores of 3 or 4. Patients with no moderate/severe symptom ratings were considered to have low symptom burden at 1‐year. Mean age at enrollment was 55.5 years with 17% African Americans. Median follow‐up was 6 years (range, 0.4–8.5 years). FACT‐BMT scores improved between enrollment and 1‐year and remained stable thereafter. Low symptom burden was reported by 27% of patients at baseline, 38% at 1‐year, and 32% at 4 years post‐AHCT. Predictors of low symptom burden at 1‐year included low symptom burden at baseline: OR 2.7 (1.8–4.1), p < 0.0001; older age: OR 2.1 (1.3–3.2), p = 0.0007; and was related to being employed: OR 2.1 (1.4–3.2), p = 0.0004). We conclude that MM survivors who achieve disease control after AHCT have excellent recovery of FACT‐BMT and subscale scores to population norms by 1‐year post‐transplant, though many patients continue to report moderate to severe severity in some symptoms at 1‐year and beyond.
Change in FACT‐BMT score between baseline and 1‐year post‐transplant after AHCT. Q4 represents the highest QOL score quartile and Q1 represents the lowest QOL score quartile.</description><identifier>ISSN: 0361-8609</identifier><identifier>ISSN: 1096-8652</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.26596</identifier><identifier>PMID: 35567778</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Autografts ; Disease control ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - therapy ; Quality of Life ; Stem cell transplantation ; Transplantation ; Transplantation, Autologous ; Transplants & implants</subject><ispartof>American journal of hematology, 2023-01, Vol.98 (1), p.140-147</ispartof><rights>2022 Wiley Periodicals LLC.</rights><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4086-fe1c59942ad6f4740eac366bda173a025cac041cea11faf9bf54674665be85b33</citedby><cites>FETCH-LOGICAL-c4086-fe1c59942ad6f4740eac366bda173a025cac041cea11faf9bf54674665be85b33</cites><orcidid>0000-0002-1092-5643 ; 0000-0001-7731-759X ; 0000-0003-2876-2886</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35567778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>D'Souza, Anita</creatorcontrib><creatorcontrib>Brazauskas, Ruta</creatorcontrib><creatorcontrib>Stadtmauer, Edward A.</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Hari, Parameswaran</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Callander, Natalie</creatorcontrib><creatorcontrib>Devine, Steven</creatorcontrib><creatorcontrib>Efebera, Yvonne</creatorcontrib><creatorcontrib>Ganguly, Siddhartha</creatorcontrib><creatorcontrib>Gasparetto, Cristina</creatorcontrib><creatorcontrib>Geller, Nancy</creatorcontrib><creatorcontrib>Horowitz, Mary M.</creatorcontrib><creatorcontrib>Koreth, John</creatorcontrib><creatorcontrib>Landau, Heather</creatorcontrib><creatorcontrib>Brunstein, Claudio</creatorcontrib><creatorcontrib>McCarthy, Philip</creatorcontrib><creatorcontrib>Qazilbash, Muzaffar H.</creatorcontrib><creatorcontrib>Giralt, Sergio</creatorcontrib><creatorcontrib>Krishnan, Amrita</creatorcontrib><creatorcontrib>Flynn, Kathryn E.</creatorcontrib><title>Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy is standard of care in multiple myeloma (MM). While short‐term quality of life (QOL) deterioration after AHCT is known, the long‐term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. FACT‐BMT scores up to 4 years post‐AHCT were analyzed. Symptom burden was studied using responses to 17 individual symptoms dichotomized as ‘none/mild’ for scores 0–2 and ‘moderate/severe’ for scores of 3 or 4. Patients with no moderate/severe symptom ratings were considered to have low symptom burden at 1‐year. Mean age at enrollment was 55.5 years with 17% African Americans. Median follow‐up was 6 years (range, 0.4–8.5 years). FACT‐BMT scores improved between enrollment and 1‐year and remained stable thereafter. Low symptom burden was reported by 27% of patients at baseline, 38% at 1‐year, and 32% at 4 years post‐AHCT. Predictors of low symptom burden at 1‐year included low symptom burden at baseline: OR 2.7 (1.8–4.1), p < 0.0001; older age: OR 2.1 (1.3–3.2), p = 0.0007; and was related to being employed: OR 2.1 (1.4–3.2), p = 0.0004). We conclude that MM survivors who achieve disease control after AHCT have excellent recovery of FACT‐BMT and subscale scores to population norms by 1‐year post‐transplant, though many patients continue to report moderate to severe severity in some symptoms at 1‐year and beyond.
Change in FACT‐BMT score between baseline and 1‐year post‐transplant after AHCT. Q4 represents the highest QOL score quartile and Q1 represents the lowest QOL score quartile.</description><subject>Autografts</subject><subject>Disease control</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - therapy</subject><subject>Quality of Life</subject><subject>Stem cell transplantation</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Transplants & implants</subject><issn>0361-8609</issn><issn>1096-8652</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kUFv1DAQhS0EokvhwB9AlrjQw7Z2EtvJBamqKAVV4lLO1sQ77nrl2KnttMqZP06WLRUgcZqR5tPTe_MIecvZKWesOoPd9rSSopPPyIqzTq5bKarnZMVqyZeddUfkVc47xjhvWvaSHNVCSKVUuyI_bhLs0JSYHGYaLb2bwLsy71fvLNKEJt5jmimEDc3zMJY40H5KGwwUbMFEYSrRx9s4ZbrFAUoco8PiDDXoPS0JQh49hALFxUBdoMPkixs90mFGHwd4TV5Y8BnfPM5j8v3y083F1fr62-cvF-fXa9OwVq4tciO6rqlgI22jGoZgain7DXBVA6uEAcMabhA4t2C73opGqkZK0WMr-ro-Jh8PuuPUD7gxGBZzXo_JDZBmHcHpvy_BbfVtvNfd_rdSLgIfHgVSvJswFz24vE8JAZf4upKyUR0TvFvQ9_-guzilsMTTlRJCtW1bqYU6OVAmxZwT2icznOl9tXqpVv-qdmHf_en-ifzd5QKcHYAH53H-v5I-_3p1kPwJWp2yWA</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>D'Souza, Anita</creator><creator>Brazauskas, Ruta</creator><creator>Stadtmauer, Edward A.</creator><creator>Pasquini, Marcelo C.</creator><creator>Hari, Parameswaran</creator><creator>Bashey, Asad</creator><creator>Callander, Natalie</creator><creator>Devine, Steven</creator><creator>Efebera, Yvonne</creator><creator>Ganguly, Siddhartha</creator><creator>Gasparetto, Cristina</creator><creator>Geller, Nancy</creator><creator>Horowitz, Mary M.</creator><creator>Koreth, John</creator><creator>Landau, Heather</creator><creator>Brunstein, Claudio</creator><creator>McCarthy, Philip</creator><creator>Qazilbash, Muzaffar H.</creator><creator>Giralt, Sergio</creator><creator>Krishnan, Amrita</creator><creator>Flynn, Kathryn E.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1092-5643</orcidid><orcidid>https://orcid.org/0000-0001-7731-759X</orcidid><orcidid>https://orcid.org/0000-0003-2876-2886</orcidid></search><sort><creationdate>202301</creationdate><title>Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma</title><author>D'Souza, Anita ; Brazauskas, Ruta ; Stadtmauer, Edward A. ; Pasquini, Marcelo C. ; Hari, Parameswaran ; Bashey, Asad ; Callander, Natalie ; Devine, Steven ; Efebera, Yvonne ; Ganguly, Siddhartha ; Gasparetto, Cristina ; Geller, Nancy ; Horowitz, Mary M. ; Koreth, John ; Landau, Heather ; Brunstein, Claudio ; McCarthy, Philip ; Qazilbash, Muzaffar H. ; Giralt, Sergio ; Krishnan, Amrita ; Flynn, Kathryn E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4086-fe1c59942ad6f4740eac366bda173a025cac041cea11faf9bf54674665be85b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Autografts</topic><topic>Disease control</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - therapy</topic><topic>Quality of Life</topic><topic>Stem cell transplantation</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>D'Souza, Anita</creatorcontrib><creatorcontrib>Brazauskas, Ruta</creatorcontrib><creatorcontrib>Stadtmauer, Edward A.</creatorcontrib><creatorcontrib>Pasquini, Marcelo C.</creatorcontrib><creatorcontrib>Hari, Parameswaran</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Callander, Natalie</creatorcontrib><creatorcontrib>Devine, Steven</creatorcontrib><creatorcontrib>Efebera, Yvonne</creatorcontrib><creatorcontrib>Ganguly, Siddhartha</creatorcontrib><creatorcontrib>Gasparetto, Cristina</creatorcontrib><creatorcontrib>Geller, Nancy</creatorcontrib><creatorcontrib>Horowitz, Mary M.</creatorcontrib><creatorcontrib>Koreth, John</creatorcontrib><creatorcontrib>Landau, Heather</creatorcontrib><creatorcontrib>Brunstein, Claudio</creatorcontrib><creatorcontrib>McCarthy, Philip</creatorcontrib><creatorcontrib>Qazilbash, Muzaffar H.</creatorcontrib><creatorcontrib>Giralt, Sergio</creatorcontrib><creatorcontrib>Krishnan, Amrita</creatorcontrib><creatorcontrib>Flynn, Kathryn E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>D'Souza, Anita</au><au>Brazauskas, Ruta</au><au>Stadtmauer, Edward A.</au><au>Pasquini, Marcelo C.</au><au>Hari, Parameswaran</au><au>Bashey, Asad</au><au>Callander, Natalie</au><au>Devine, Steven</au><au>Efebera, Yvonne</au><au>Ganguly, Siddhartha</au><au>Gasparetto, Cristina</au><au>Geller, Nancy</au><au>Horowitz, Mary M.</au><au>Koreth, John</au><au>Landau, Heather</au><au>Brunstein, Claudio</au><au>McCarthy, Philip</au><au>Qazilbash, Muzaffar H.</au><au>Giralt, Sergio</au><au>Krishnan, Amrita</au><au>Flynn, Kathryn E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2023-01</date><risdate>2023</risdate><volume>98</volume><issue>1</issue><spage>140</spage><epage>147</epage><pages>140-147</pages><issn>0361-8609</issn><issn>1096-8652</issn><eissn>1096-8652</eissn><abstract>Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy is standard of care in multiple myeloma (MM). While short‐term quality of life (QOL) deterioration after AHCT is known, the long‐term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. FACT‐BMT scores up to 4 years post‐AHCT were analyzed. Symptom burden was studied using responses to 17 individual symptoms dichotomized as ‘none/mild’ for scores 0–2 and ‘moderate/severe’ for scores of 3 or 4. Patients with no moderate/severe symptom ratings were considered to have low symptom burden at 1‐year. Mean age at enrollment was 55.5 years with 17% African Americans. Median follow‐up was 6 years (range, 0.4–8.5 years). FACT‐BMT scores improved between enrollment and 1‐year and remained stable thereafter. Low symptom burden was reported by 27% of patients at baseline, 38% at 1‐year, and 32% at 4 years post‐AHCT. Predictors of low symptom burden at 1‐year included low symptom burden at baseline: OR 2.7 (1.8–4.1), p < 0.0001; older age: OR 2.1 (1.3–3.2), p = 0.0007; and was related to being employed: OR 2.1 (1.4–3.2), p = 0.0004). We conclude that MM survivors who achieve disease control after AHCT have excellent recovery of FACT‐BMT and subscale scores to population norms by 1‐year post‐transplant, though many patients continue to report moderate to severe severity in some symptoms at 1‐year and beyond.
Change in FACT‐BMT score between baseline and 1‐year post‐transplant after AHCT. Q4 represents the highest QOL score quartile and Q1 represents the lowest QOL score quartile.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>35567778</pmid><doi>10.1002/ajh.26596</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1092-5643</orcidid><orcidid>https://orcid.org/0000-0001-7731-759X</orcidid><orcidid>https://orcid.org/0000-0003-2876-2886</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2023-01, Vol.98 (1), p.140-147 |
| issn | 0361-8609 1096-8652 1096-8652 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9659666 |
| source | Wiley |
| subjects | Autografts Disease control Hematology Hematopoietic Stem Cell Transplantation - adverse effects Humans Middle Aged Multiple myeloma Multiple Myeloma - therapy Quality of Life Stem cell transplantation Transplantation Transplantation, Autologous Transplants & implants |
| title | Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A08%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trajectories%20of%20quality%20of%20life%20recovery%20and%20symptom%20burden%20after%20autologous%20hematopoietic%20cell%20transplantation%20in%20multiple%20myeloma&rft.jtitle=American%20journal%20of%20hematology&rft.au=D'Souza,%20Anita&rft.date=2023-01&rft.volume=98&rft.issue=1&rft.spage=140&rft.epage=147&rft.pages=140-147&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.26596&rft_dat=%3Cproquest_pubme%3E2664790519%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4086-fe1c59942ad6f4740eac366bda173a025cac041cea11faf9bf54674665be85b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2755788827&rft_id=info:pmid/35567778&rfr_iscdi=true |